Results 251 to 260 of about 162,477 (300)

Neutrophil migration participates in the side effect of recombinant human tissue plasminogen activator. [PDF]

CNS Neurosci Ther
Huang Y, Han Z, Shen T, Zheng Y, Yang Z, Fan J, Wang R, Yan F, Tao Z, Luo Y, Liu P.   +10 more
europepmc   +1 more source

Myelin basic protein stimulates plasminogen activation via tissue plasminogen activator following binding to independent l-lysine-containing domains

, 2017
Mario Gonzalez–Gronow, Jenny L. Fiedler, Cristian Farias Gomez, Fang Wang, Rupa Ray, Paul Ferrell, Salvatore V. Pizzo   +6 more
openalex   +2 more sources

Risk Factors for Cardiovascular and Metabolic Disease: Integrating Traditional and Novel Paradigms

iNew Medicine, Volume 1, Issue 1, December 2025.
ABSTRACT Cardiovascular and metabolic diseases (CVMD), encompassing atherosclerotic cardiovascular disease (ASCVD), heart failure, obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD), remain the leading global cause of morbidity and mortality.
Zhihua Wang, Shuo Chen, Suowen Xu, Jianping Weng   +3 more
wiley   +1 more source

Use of recombinant tissue plasminogen activator (rTPA) for treatment of fibrin in the anterior chamber of the horse. [PDF]

Vet Med Sci
Pereira R, Bowen M, Rapezzano G, Redpath A, Pratt S, Hallowell G.   +5 more
europepmc   +1 more source

Four Pharmacogenomic Variants Strongly Linked to Corticosteroid‐Induced Avascular Necrosis in Children with Cancer

The Journal of Clinical Pharmacology, Volume 65, Issue 12, Page 1844-1854, December 2025.
Abstract Corticosteroids are effective anti‐cancer agents for treating hematologic malignancies in children. However, avascular necrosis (AVN) is a common and debilitating adverse effect, leading to bone death and impacting long‐term quality of life. This study aimed to uncover the genetic factors contributing to corticosteroid‐induced AVN in a well ...
Miguel Cordova‐Delgado, Erika N. Scott, Shahrad R. Rassekh, Catrina M. Loucks, Wan‐Chun Chang, Edward J. Raack, Jessica N. Trueman, Colin J. D. Ross, Bruce C. Carleton, the Canadian Pharmacogenomics Network for Drug Safety Consortium   +9 more
wiley   +1 more source

Early Drainage of Macula-Involving Massive Suprachoroidal Haemorrhage Assisted with Recombinant Tissue Plasminogen Activator May Lead to Better Visual Prognosis. [PDF]

Case Rep Ophthalmol
Khalil M, Schneiders M, Veckeneer M, Depla JA, Feron E, Saidkasimova S.   +5 more
europepmc   +1 more source

Ovarian Aging: Mechanisms, Age‐Related Disorders, and Therapeutic Interventions

MedComm, Volume 6, Issue 12, December 2025.
A comprehensive overview of the molecular mechanisms underlying ovarian aging, its association with age‐related diseases, and potential therapeutic interventions. Ovarian aging involves DNA damage, mitochondrial dysfunction, oxidative stress, telomere attrition, and follicular depletion, driving age‐related infertility, menopause, and multiple systemic
Xingyu Liu, Yuanqu Zhao, Yanzhi Feng, Shixuan Wang, Jinjin Zhang   +4 more
wiley   +1 more source

Synergistic effects of neuroprotective drugs with intravenous recombinant tissue plasminogen activator in acute ischemic stroke: A Bayesian network meta-analysis. [PDF]

PLoS One
Dang C, Wang Q, Zhuang Y, Li Q, Lu Y, Xiong Y, Feng L.   +6 more
europepmc   +1 more source

Effect of Thrombopoietin Receptor Agonist Romiplostim on the Ionizing Radiation‐Induced Premature Aging

Pharmacology Research &Perspectives, Volume 13, Issue 6, December 2025.
Mice irradiated with 5 Gy every 4 weeks (total dose of 10 Gy over 2 months) showed a significant aging phenotype, but thrombopoietin receptor agonist Romiplostim (RP) treatment partially ameliorate radiation‐induced premature aging. ABSTRACT Environmental stressors, such as ionizing radiation, accelerate aging by causing DNA damage and triggering ...
Masaru Yamaguchi, Tokuhisa Hirouchi, Yoshiaki Sato, Ikuo Kashiwakura   +3 more
wiley   +1 more source

Combined treatment of submacular hemorrhage with low-dose subretinal recombinant tissue plasminogen activator and intravitreal conbercept. [PDF]

BMC Ophthalmol
Ma Y, Rao S, Tan Y, Du H, Sun X.
europepmc   +1 more source